**Bifidobacterium animalis** subsp. **lactis** HN019 Effects on Gut Health: A Review

Jing Cheng*, Arja Laitila and Arthur C. Ouwehand

International Flavors & Fragrances Inc., Global Health and Nutrition Science, Danisco Sweeteners Oy, Kantvik, Finland

Optimal gut motility is central to bowel function and gut health. The link between the gut dysmotility related disorders and dysfunctional-intestinal barriers has led to a hypothesis that certain probiotics could help in normalizing gut motility and maintain gut health. This review investigates the roles of *Bifidobacterium animalis* subsp. *lactis* HN019 (*B. lactis* HN019™) on gut health, and its mechanisms of action in various pre-clinical and clinical studies. Research supports the hypothesis that *B. lactis* HN019™ has a beneficial role in maintaining intestinal barrier function during gastrointestinal infections by competing and excluding potential pathogens via different mechanisms; maintaining normal tight junction function in vitro; and regulating host immune defense toward pathogens in both in vitro and human studies. This has been observed to lead to reduced incidence of diarrhea. Interestingly, *B. lactis* HN019™ also supports normal physiological function in immunosenescent elderly and competes and excludes potential pathogens. Furthermore, *B. lactis* HN019™ reduced intestinal transit time and increased bowel movement frequency in functional constipation, potentially by modulating gut–brain–microbiota axis, mainly via serotonin signaling pathway, through short chain fatty acids derived from microbial fermentation. *B. lactis* HN019™ is thus a probiotic that can contribute to relieving gut dysmotility related disorders.

**Keywords:** bowel function, diarrhea, gut motility, *Bifidobacterium animalis* subsp. *lactis* HN019, intestinal barrier, probiotic, gut-brain

**INTRODUCTION**

Bowel function plays a central role in gut health and overall well-being. A healthy gut involves many factors, including intact epithelial barrier function, homeostatic intestinal microbiota, optimal functioning digestive organs (stomach, liver/gallbladder, pancreas), and definitely optimal gut motility. The interactions of those systems are in homeostasis in healthy subjects with normal bowel function and balanced immune function. However, this can be perturbed by antibiotic usage, unbalanced diet, and other lifestyle factors, infections, and other disease conditions. This may lead to changes in bowel habits and stool consistency, diarrhea, constipation, or a spectrum of both, such as manifested in different subtypes of irritable bowel syndrome (IBS) (1–3).

The human gastrointestinal tract (GIT) represents an extremely complex ecosystem, comprising of interactions within the digestive system as well as cross-functioning with various immune cells, endocrine cells, and nerve cells, and organ systems beyond the GIT (4–6). Evidence also showed that the interactions between GIT and other organs often involve the residential intestinal microbiota, which is a dense community (estimated to $4 \times 10^{13}$ microbial cells), contributing to
various metabolic functions, and immunological defenses in the maintenance of normal health (7–9). Therefore, gut health has traditionally been one of the most important targets for the majority of probiotic applications, and central for connections to other health benefits via the intestinal microbiota.

Probiotics are defined as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host (10). Studies have shown that probiotics are beneficial for supporting the human body’s natural functions in both health and disease; either by interacting with the host directly or indirectly by optimizing the composition and/or activity of the intestinal microbiota. Although common probiotic benefits have been proposed, the core benefits are strain-specific (10).

*Bifidobacterium animalis* subsp. *lactis* HN019™ (*B. lactis* HN019™) is a strain originally isolated from commercial yogurt, and commercialized as an ingredient for dietary supplements, fermented and non-fermented foods, and beverages for decades (11). Its complete genome sequence was published in 2018 (12), allowing for stringent control of product quality, safety, purity, and consistency by strain identity confirmation at industrial scale. *B. lactis* HN019™ is available in various finished formats, granting it profound application potential in food and beverage, dietary supplement, and pharmaceutical industries.

The objective of this review is to discuss the properties of *B. lactis* HN019™ in the context of both preclinical and clinical studies on the following aspects of gut health: survival through the gut, modulation of intestinal microbiota, maintain intestinal barrier functions during gastrointestinal infections, regulate gut motility, and improve symptoms in constipation, assist digestion, and utilization of macronutrients, and their plausible mechanisms of action. Further, the safety of the strain will be discussed. Although the same strain has been investigated for other health benefits (13), these will not be discussed here.

**SAFETY**

*Bifidobacterium animalis* subsp. *lactis* has been documented to be present in human food since 1980 but most likely has been consumed before that. The species is listed in Inventory of Microbial Food Cultures with Safety Demonstration in Fermented Food Products (14). The European Food Safety Authority (EFSA) has included the subspecies in the Qualified Presumption of Safety list (15). In China, *B. lactis* HN019™ has been specifically permitted for use in infant and toddler (>1 year) food since 2011 (16), and it was accepted to be Generally Recognized as Safe (GRAS, GRN445) in US in 2012 (17).

By December 2020, there were 42 studies/clinical trials published for 27 investigated cohorts, including both healthy and compromised subjects in all age groups from newborns to elderly (Table 1). The investigational products contain *B. lactis* HN019™ as a single strain or combined with other probiotics and/or prebiotics. The daily dosage of *B. lactis* HN019™ in the products ranged from $10^7$ to $10^{11}$ colony forming units (CFU) per day and consumption lasted for 7 days to 2 years. None of these trials have reported any safety concerns related to *B. lactis* HN019™ consumption, and it may be concluded that infants, children, adults, and seniors can safely consume *B. lactis* HN019™ at doses up to $3 \times 10^{11}$ CFU/day.

To date, most of the published human studies for *B. lactis* HN019™ focused on gut health of which six studies contained *B. lactis* HN019™ as a single strain product in at least one arm (Table 2).

**SURVIVAL THROUGH THE GUT**

Although not stipulated in the definition, it is often assumed that probiotic strains should be able to survive passage through the digestive system, transiently colonize in the GIT, and potentially modulate host factors, such as immune responses, digestion, or the intestinal microbiota composition and/or activity. These probiotic attributes may be observed more pronounced in subjects with suboptimal physiological status but are often not observed in the healthy subjects. These functional characterizations can be investigated in various *in vitro* and/or animal models, while ultimately, health efficacy can only be confirmed by human clinical studies (64). Although adhesion is not a pre-requisite for a strain to elicit probiotic properties, interaction with intestinal epithelial cells (IECs) and intestinal mucosa is considered important for colonization and modulation of host factors. The excellent adhesion property of *B. lactis* HN019™ to IEC lines, such as HT29, Caco-2, and HT29-MTX, were documented *in vitro* in comparison with two other probiotic *lactobacilli* strains and a negative control (non-probiotic *Lactobacillus bulgaricus*) (65).

*B. lactis* HN019™ demonstrates high tolerance to low pH and varying resistance to bile salts *in vitro*, which are two important markers for assessing survival during intestinal passage (66). So far, five human clinical studies from four cohorts investigated the survival and transient colonization of *B. lactis* HN019™ in interventions, of which only Gopal et al. (59) identified *B. lactis* HN019™ at strain level (Supplementary Table 1) (24, 25, 35, 58, 59). Regardless of the variations caused by different quantitative techniques, given the observations that *B. lactis*/bifidobacteria was/were not detected in the control group (24) or counts decreased after the cessation of the supplementation (35, 58), it is highly likely that *B. lactis*/bifidobacteria detected in the probiotic group in these studies was *B. lactis* HN019™. These studies suggest that *B. lactis* HN019™ could survive and transiently persist in intestinal transit in both short-term (2–4 weeks) and long-term (>6 months) dietary interventions in almost all age groups, including infants, toddlers, pre-school children, adults, and elderly. This, notwithstanding a high inter-individual variability (0.1–68.8%) of *B. lactis* HN019™ colonies quantified by strain-specific probes from total fecal bifidobacteria was reported.
| Daily dose of B. lactis HN019™ (total probiotic potency in blend, CFU) | Subjects receiving products containing B. lactis HN019™ (N) | Age of subjects (median/mean, years) | Duration of supplementation (week) | Product format (delivery vehicles) | Other ingredients used in serum | Reference |
|---|---|---|---|---|---|---|
| Influence on digestive system | Healthy elderly | 65–90 (75.3) | 24 | NR (powder) | L. paracasei Lpc-37, L. rhamnosus HN001, L. acidophilus NCFM, FOS (18) |
| | Adult constipation | 19–70 (25.7) | 30 days | Capsule | L. acidophilus NCFM, L. casei Lc-11, Lactococcus lactis Li-23, B. bifidum BB-06 (19) |
| | Constipated adult women | 22–60 (36.84) | 6 | Sachet (water) | L. rhamnosus SP1 100MLD, L. casei F19, L. acidophilus La-14, B. longum BB536, B. bacterium Hi-16V, inulin (20) |
| | Healthy female colleague students | 2–4 (38 months) | 9 months | Capsule (milk) | NA (24, 25) |
| | Constipated young adults | 18–45 (31.5) | 2 | Yogurt | Polysaccharides, L. acidophilus NCFM (26) |
| | Constipation adults | 18–65 (NR) | 30 days | Sachet (water) | L. paracasei Lpc-37, L. acidophilus HN001, L. acidophilus NCFM, FOS GOS (27–30) |
| | Healthy children | 1–4 (21.7 months at baseline) | 1 year | Reconstituted milk | NA (41, 42) |
| | Healthy full-term Infants | 2–6 weeks (NR) | 1 year | Infant formula | Gangliosides, FOS, long-chain polyunsaturated fatty acids (31) |
| | Adult constipation | 25–65 (44 in high dose, 44 in low dose) | 2 | Capsule (yogurt) | NA (32) |
| | Pregnancy week 35–6 post-partum | Mothers: 35–6 post-partum, if breast feeding, and children: 2 years | | | | |
| | Infants at risk of allergies | 2–16 days at baseline (6 days) | | Capsule (water, formula, breast milk, or food) | NA (35–42) |
| | Infants at risk of allergies | 2–16 days at baseline | | Capsule (milk) | NA (37) |
| | Mother-baby pairs | Mother: NR | 2–6 weeks before delivery to 6 months post-partum, if breast feeding, and children: 2 years | Capsule (milk) | NA (43) |
| | Children with atopic eczema | Mother: NR | | Capsule (milk) | L. rhamnosus HN001 (44) |

(Continued)
| Daily dose of *B. lactis* HN019™ (total probiotic potency in blend, CFU) | Subjects receiving products containing *B. lactis* HN019™ (N) | Age of subjects (median/mean, years) | Duration of supplementation (week) | Product format (delivery vehicles) | Other ingredients used in serum Reference |
|---|---|---|---|---|---|
| 5 × 10⁸ | 14 | 60–84 (69.5) | 3 | Sachet (milk) | NA (45) |
| High dose: 5 × 10¹⁰ Low dose: 5 × 10⁸ | 30 | 63–84 (46) | 3 | Reconstituted milk | NA (47) |
| 5 × 10¹⁰ | 50 | 41–81 (48) | 3 | Reconstituted milk | NA (49) |
| 3 × 10¹¹ | 13 | 62–83 (50) | 6 | Reconstituted milk | NA (51) |

**Other gut health-related benefits**

| High dose: 3 × 10⁸ (2 × 10¹⁰) Low dose: NR (1 × 10¹⁰) | 14 | 0 | 4 | NR (breastmilk) | *B. lactis* Bi-07, *L. rhamnosus* HN001, GOS (52) |
| 2 × 10⁸-10⁹ (8 × 10⁶-10⁷) | 25 | 65–90 (75.3) | 24 | Powder (NR) | *L. paracasei* Lpc-37, *L. rhamnosus* HN001, *L. acidophilus* NCFM, FOS (53) c |
| 9 × 10³ | 171 | 2–16 days at baseline (6 days) | Mothers: pregnancy week 35 to 6 m post-partum, if breastfeeding, and children: 0–2 years | Capsule (water, formula, breast milk, or food) | NA (54, 55) c |
| NR (2 × 10⁹) | 73 | NR (60.9) | 7 days | Powder (water) | *L. paracasei* Lpc-37, *L. rhamnosus* HN001, *L. acidophilus* NCFM, FOS (56) |
| 2 × 10⁶ (8 × 10⁵) | 49 | NR (64.5) | 5 days prior to surgery and for 14 days after surgery | Sachet (NR) | *L. paracasei* Lpc-37, *L. rhamnosus* HN001, *L. acidophilus* NCFM, FOS (57) |
| High dose: 5 × 10⁹ Medium dose: 1 × 10⁷ Low dose: 6.5 × 10⁷ | 60 | 60–87 (67 in high dose, 70 in medium/dose) | 4 | Reconstituted milk | NA (58) |
| 3 × 10¹⁰ | 10 | 20–60 (NR) | 4 | Reconstituted milk | NA (59) |

**Non-gut health related benefits**

| 10⁴-10⁷ | 20 | >30 (NR) | 30 days | Lozenge | NA (60) |
| 10⁹ (4 × 10⁹) | 19 | 34–50 (43.3) | 8 | Sachet (NR) | *L. paracasei* Lpc-37, *L. rhamnosus* HN001, *L. acidophilus* NCFM (61) |
| 2.72 × 10¹⁵ | 19 | 18–60 (48.05) | 90 days | Fermented milk | NA (62) |
| 2.72 × 10¹⁵ | 26 | 18–60 (NR) | 45 days | Fermented milk | NA (63) |

CFU, colony forming unit; CRC, colorectal cancer; FOS, fructo-oligosaccharide; FC, functional constipation; IBS-C, constipation dominant irritable bowel syndrome; GOS, galacto-oligosaccharide; NA, not applicable; NR, not reported.

* The article only mentioned CFU/g, but not the g for the finished format.
* Studies published from the same cohort first described in Wickens et al. (36).
* Studies published from the same cohort first described in de Carvalho et al. (33).
in healthy adults (59). Fecal recovery has also been assessed with products containing \textit{B. lactis HN019}\textsuperscript{TM} in combination with other active components, such as prebiotics where increases in \textit{B. lactis} or \textit{B. lactis HN019}\textsuperscript{TM} were observed (31, 34). However, Horvath et al. (67) did not observe such increases with a multi-strain probiotic containing \textit{B. lactis HN019}\textsuperscript{TM} (67).

**MODULATION OF INTESTINAL MICROBIOTA**

\textit{Bifidobacterium} and \textit{Lactobacillus sensu lato} have long been used in processing and preserving food and are considered as beneficial (68). Although they are not the most abundant, they are relatively stable in the adult intestinal microbiota, maintaining essential metabolic functions, such as fermentation of undigested carbohydrates into short-chain fatty acids (SCFAs), lipid metabolism, and vitamin synthesis throughout the entire lifespan (69, 70). This balance could be breached during aging, where the gut microbiota become less diverse and total bifidobacterial counts decrease (71). Therefore, sustaining these two genera at a stable level may be beneficial for maintaining a balanced healthy gut microbiota, particularly for elderly. \textit{B. lactis HN019}\textsuperscript{TM} can become a significant component of the normal fecal bifidobacterial population, and can increase total \textit{Lactobacillus sensu lato} and \textit{Bifidobacterium} spp. counts in feces, with daily consumption of \(6.5 \times 10^7\) CFU to \(3 \times 10^{10}\) CFU (58, 59). There were no significant differences between the responses of the different dose groups, indicating that even the lowest dose (\(6.5 \times 10^7\) CFU/day) was able to confer desired changes with regards to these two beneficial bacterial groups in the intestinal microbiota (58). Furthermore, in these two studies fecal bifidobacterial and Lactobacilli counts decreased to baseline levels after cessation of the supplementation, remaining at \(10^8\textendash 10^9\) CFU/g for bifidobacteria and \(10^7\textendash 10^8\) CFU/g for lactobacilli. Interestingly, Ahmed et al. (58) reported significant increases in enterococci in the placebo group during the intervention with healthy elderly subjects. Although enterococci are normal members of the colonic microbiota, they are also opportunistic pathogens and may increase during aging (72). Moreover, in the same study, enterococci were reduced significantly in the same group during \textit{B. lactis HN019}\textsuperscript{TM} consumption, indicating that \textit{B. lactis HN019}\textsuperscript{TM} can reduce levels of fecal enterococci in elderly (58).

\textit{B. lactis HN019}\textsuperscript{TM} was shown to support maintaining the healthy/normal intestinal microbiota against aging process and by competing and excluding harmful pathogens, both at taxonomical and functional levels (25, 58, 59). In addition, further evidence for intestinal microbiota support can be found from combination products containing \textit{B. lactis HN019}\textsuperscript{TM}. For example, both \textit{B. lactis HN019}\textsuperscript{TM} (\(10^9\) CFU/day) alone or with polydextrose (6.25 g/day) for 2 weeks increased the proportion of fecal \textit{Bacteroides} in healthy young Japanese females, while the synbiotic format had better synergistic outcomes than probiotic alone, in terms of greater proportion of this genus among the entire microbial community (23). In a recent pilot study in Chinese neonates, after 28 days supplementation with a \textit{B. lactis HN019}\textsuperscript{TM} synbiotic since birth, the complexity and similarity of gut microbiota in cesarean-born neonates across time and across individuals were similar to those in the vaginally-born infants (52). Furthermore, both \textit{Bifidobacterium} and \textit{Lactobacillus} increased in their abundances after the third day of the intervention.

**TABLE 2** Use of \textit{B. lactis HN019}\textsuperscript{TM} as single-strain products in human clinical trials for gut health.

| Dose (CFU/day) | Subjects (N) in HN019 arm | Age (mean\(^a\), years) | Duration (week) | Product format | Endpoints | Reference |
|---------------|---------------------------|-------------------------|-----------------|----------------|----------|-----------|
| High dose: \(1 \times 10^{10}\) Low dose: \(1 \times 10^9\) | 152 Adult constipation | 18–70 (41.7) | 4 | Capsule | CTT, BMF, SC | (22) |
| \(1 \times 10^9\) | 7 Young female with constipation | >18 (NR) | 2 | Sachet | BMF, SC | (23) |
| High dose: \(1.72 \times 10^{10}\) Low dose: \(1.8 \times 10^9\) | 66 Adult constipation | 25–65 (44 in high dose, 44 in low dose) | 2 | Capsule | WGTT, BMF | (32) |
| \(5 \times 10^9\) | 130 Healthy preschool children | 2–4 (38 months) | 9 months | Capsule | Incidence and duration of diarrhea | (24, 25) |
| High dose: \(5 \times 10^8\) Medium dose: \(1 \times 10^9\) Low dose: \(6.5 \times 10^7\) | 60 Healthy elderly | 60–87 (67 in high dose, 70 in medium/dose) | 4 | Reconstituted milk | Fecal microbiota | (58) |
| \(3 \times 10^{10}\) | 10 Healthy adults | 20–60 (NR) | 4 | Reconstituted milk | Fecal microbiota | (59) |

BMF: bowel movement frequency; CFU: colony forming unit; CTT: colonic transit time; IBS-C: constipation dominant irritable bowel syndrome; CRC: colorectal cancer; FC: functional constipation; NR: not reported; SC: stool consistency; WGTT: whole gut transit time.

\(^a\)Mean or Median.
These findings from *B. lactis* HN019™ alone or in combination with other ingredients indicate that the above-mentioned modulations of the intestinal microbiota are ubiquitous, across age and geography.

**MAINTAIN INTESTINAL BARRIER FUNCTIONS DURING GASTROINTESTINAL INFECTIONS**

Gastrointestinal infections often lead to diarrhea in humans, which was estimated as a leading cause of death among all ages across the world (73). Rotavirus, *Shigella* spp., and *Salmonella* spp. are the top three etiologies for diarrhea mortality, whereas the first two are typical for children under the age of five (73). The leading risk factors for diarrhea were unchanged from 2005 to 2015, which are poor hygiene in water supply and food chain, where bacterial pathogens are food poisoning organisms (73).

The gut forms the border between the inside (body) and the outside (lumen), an intestinal barrier is therefore indispensable and includes both a physical and an immunological barrier, preventing pathogenic bacteria and other harmful substances from entering the body while at the same time allowing nutrients and water to be absorbed. Intestinal barrier integrity is a prerequisite for homeostasis of mucosal function, which is balanced to maximize absorptive capacity, while maintaining efficient defensive reactions against chemical and microbial challenges.

**B. lactis HN019™ Maintains Epithelium Integrity**

The inner surface of the intestine consists of a layer of cells (epithelium), which are covered by a mucus layer (a viscoelastic layer consisting mainly of protein-linked carbohydrates) which plays a key role in the barrier effect mechanism.

Tight junctions (TJ) are cell–cell junctional complexes that form a continuous intercellular barrier between epithelial cells, that the major components are claudin and occludin proteins (74). These structures control and maintain balanced intestinal permeability. Increased permeability is associated with disease conditions, which are often characterized with intestinal mucosal inflammation (74). Therefore, a proper regulation of the function of TJ is important in health maintenance and disease prevention. Putaala et al. (75) showed that cell-free supernatant (CFS) of *B. lactis* HN019™ may increase the strength of TJ, measured as trans-epithelial electrical resistance (TEER), although not to an extent that is statistically significant, while CFS of enterohemorrhagic *Escherichia coli* (EHEC) reduced the TEER significantly (75).

Cyclooxygenases (COX) play a role in normal physiological function as well as fight against pathogenic bacteria. There are two isoforms of COX in humans: COX-1, contributing to the maintenance of the physiological functions, whereas COX-2 as an inducible enzyme mediates pathogenic inflammatory responses (75). In Putaala et al. (75), CFS of both *B. lactis* HN019™ and EHEC exhibited significant increase in the ratio of COX-2 to COX-1, but the underlying mechanisms are different. EHEC CFS induced increase of COX-2 and decrease of COX-1, whereas *B. lactis* HN019™ CFS induced a slightly increase of COX-2 and retained level of COX-1, confirming the immunostimulatory properties of *B. lactis* HN019™, which lead to the activation and maintenance of normal physiological function in elderly under immunosenescence, but not pathological inflammation (47, 76).

**B. lactis HN019™ Shows Competitive Advantages Against Entero-Pathogens**

Pre-treatment of EHEC with CFS of *B. lactis* HN019™ reduced the culturable *E. coli* numbers along with their invasive ability and cell association characteristics of the pathogenic strain (65). Both *B. lactis* HN019™ and *Salmonella typhimurium* adhere effectively to INT-407 cells, and the adhesive capacity of *B. lactis* HN019™ was similar to *S. typhimurium*. Nevertheless, the adhesion values obtained in co-treated assays showed that *B. lactis* HN019™ could significantly decrease the number of attached *S. typhimurium* while the number of attached *B. lactis* HN019™ was not affected by *S. typhimurium* (77).

**B. lactis HN019™ Regulates Host Immune Defense Toward Pathogens**

*B. lactis* HN019™ showed potential to protect enterocytes from inflammatory responses induced by *S. typhimurium* and lipopolysaccharide (LPS) *in vitro*. A robust interleukin (IL)-8 expression was induced when INT-407 cells were exposed to *S. typhimurium*. However, live and heat-killed *B. lactis* HN019™ not only functionally modulated the epithelium by inhibiting the constitutive mRNA level of IL-8 and attenuating *S. typhimurium*-induced IL-8 gene expression, but also protect the INT-407 cells from IL-8 protein production activated by LPS. Similar results were discovered on tumor necrosis factor (TNF)-α and IL-1β gene expression. TNF-α expression was up-regulated by live *B. lactis* HN019™, but the expression levels were much lower than with *S. typhimurium* (77).

Both *S. typhimurium* and EHEC are important causes of food poisoning under poor hygienic conditions, whereas *E. coli* and rotavirus are common causes of diarrhea in infants and young animals. The latter two infectious agents also commonly cause diarrhea in piglets during weaning, making piglets an ideal model for studying this type of gastrointestinal infections. The administration of *B. lactis* HN019™ to weaning piglets resulted in a significantly lower incidence of diarrhea during the first 2 days after weaning. The fecal levels of *E. coli* and rotavirus were also lower in the treatment group, which exhibited a significantly higher titer of specific antibodies in the feces (78). In addition, in mice models, *B. lactis* HN019™ was found to protect the animals against *S. typhimurium* and EHEC with lower rate of morbidity (79, 80). The probiotic-fed mice also showed significantly higher numbers of phagocytic active leukocytes (80). These findings indicated a mechanism of enhanced immune-mediated protection by *B. lactis* HN019™ against gastrointestinal infections. Moreover, in a large randomized trial in India, *B. lactis* HN019™ showed efficacy in reducing the incidence of diarrhea and fever during the rainy season (months August and September), when incidence of diarrhea is the highest (24). Fecal
immunoglobulin (Ig)A and serum inflammatory marker IL-8 were also significantly decreased in the B. lactis HN019™ arm compared to placebo (24). Similar observations were made with B. lactis HN019™ in combination with galacto-oligosaccharides (GOS); reducing the incidence of dysentery and showing a trend ($p = 0.08$) for reduced incidence of diarrhea (28).

**REGULATE GUT MOTILITY AND IMPROVE SYMPTOMS IN CONSTIPATION**

Constipation without identifiable organic causes, may refer to slow-transit constipation (STC) or obstruction constipation, which are related to poor lifestyles, such as high fat/protein diet and lack of fiber and liquid intake and exercise. The typical clinical symptom of STC is the prolonged gut transit time (GTT), which may be resulted from the dysfunction of colonic smooth muscles (81).

B. lactis HN019™ showed prokinetic effects on subjects suffering functional constipation (FC). For example, daily intake of B. lactis HN019™ at both high (1.72 × 10¹⁰ CFU) and low (1.8 × 10⁹ CFU) doses for 2 weeks decreased colonic transit time (CTT) in 100 constipated adults, with no change observed in the placebo group (32). This finding of shorten CTT was not observed in Ibarra et al. (22), who investigated the effects of B. lactis HN019™ using a similar intervention regime but longer duration (4 weeks) in 228 constipated adults diagnosed with the same ROME III criteria as in Waller et al. (32). However, a subgroup of subjects ($N = 65$) with bowel movement frequency (BMF) of less than three bowel movements per week (i.e., those who were constipated) benefitted from the consumption of the strain (22). After 4 weeks, daily doses of 10¹⁰ CFU (high does) and 10⁹ CFU (low dose) increased 2 and 1.7 bowel movements/week, respectively. The stool consistency outcomes indicated that the participants in Ibarra et al. (22) were mild-constipated subjects (Bristol Stool Scale: 3.3) without changing their level of constipation after the intervention. However, Aoe et al. (23) did not observe an effect of B. lactis HN019™ alone on BMF in constipated women after 2-week supplementation. The study population was, however, under-powered; with only seven subjects per treatment group (23). In the same study, Aoe et al. (23) explored the outcomes on stool characteristics in a symbiotic intervention arm, where polydextrose (6.25 g/day) and B. lactis HN019™ (10⁹ CFU/day) were combined. This symbiotic showed increased stool amounts which positively correlated with the relative abundance of Bacteroides. It is important to note that PDX has been reported to positively influence stool consistency and bowel function (82). Other studies with B. lactis HN019™ in combination with other probiotics or prebiotics observed improvements after intervention in bowel functions, such as shortened CTT (26), increased stool frequency and consistency (18, 27), reduced flatulence symptoms (21). However, although Botelho et al. observed a change in fecal microbiota composition, the study failed to observe a positive effect on bowel function as compared to the placebo group (19) (Table 1).

These observations on bowel habits led to the hypothesis that B. lactis HN019™ affects colonic motility patterns, which most probably via direct interactions with host factors rather than alteration of water and electrolyte secretion, even though improvements for stool amount were observed in combination with polydextrose, which is a soluble fiber. This hypothesis was investigated in an ex vivo model, where B. lactis HN019™ extract markedly increased the contractile amplitude of synchronous contractions spanning the proximal colon to the rectum. Interestingly, this effect occurred post-treatment (83). Even though the exact components of B. lactis HN019™ extract are not clear, several potential mechanistic pathways including potential active molecules will be reviewed below (Figure 1).

**Modulate Microbiota–Fermentation–Gut–Brain Signaling**

The primary pathophysiological mechanism for constipation is gut dysmotility, presenting dysregulated or deficient colonic propulsive motor patterns (6, 84). So far, molecules reported to impact on gut motility are SCFAs, formylated peptides, and serotonin (5-hydroxytryptamine, 5-HT), which might be derived from bacterial surface structures or bacterial fermentation of nutrients (6, 85). Short-chain fatty acid concentrations can directly influence motility through the G protein-coupled receptor (GPR) 41 and GPR43, where the underlying mechanisms have been mostly addressed in animal studies (86–88). For example, intra-luminal administration of a blend of acetate, propionate and butyrate in rat was shown to lead to an increased 5-HT concentration and subsequently decreased CTT (86). B. lactis HN019™ has been shown to produce lactate and acetate, where acetate was more selective potent agonist for GPR43 (48, 89). However, there are few studies confirming the effects of SCFAs on motility in humans (90, 91).

In addition, B. lactis HN019™ may also influence gut motility via gut commensals, which are known to be involved in serotonin biosynthesis and bile acid metabolism (92, 93). Bile salts are known to stimulate colonic contractility and transit in humans (94–96), where probiotic strains may deconjugate bile salts, leading to the formation of secondary bile salts with laxative effects (6). However, to date, no data is available on the ability of B. lactis HN019™ to deconjugate bile salts.

**Improve Gastrointestinal Symptoms in Constipation**

Except bowel habits, B. lactis HN019™ has been reported to reduce the frequency of functional gastrointestinal symptoms in adults, including vomiting, regurgitation, abdominal pain, nausea, gurgling, constipation, diarrhea, and flatulence (32). Most symptoms improved in the high dose (eight of nine symptoms) and low dose (seven of nine symptoms) groups, respectively, while only two of nine symptoms showed a statistically significant improvement with placebo. In Ibarra et al. (22), when comparing the measured gastrointestinal symptoms between subjects taken B. lactis HN019™ vs. placebo, only a reduction observed in the degree of straining in the subgroup of subjects (BMF < 3). Improvements of gastrointestinal symptoms were also observed in studies with B. lactis HN019™...
in combination with other probiotics or prebiotics (21, 27) (Table 1).

ASSIST DIGESTION AND UTILIZATION OF MACRONUTRIENTS

Some of the constipation related symptoms are associated with inadequate digestion of fibrous components from the diet. Plant-based diets, rich in fermentable residues, could be a solution to constipation but may be accompanied with complaints of gas produced during endogenous microbial fermentation. Aiding their digestion may thus help reduce these symptoms. In vitro, B. lactis HN019™ was shown to utilize commercial oligosaccharides: FOS, GOS, and xylo-oligosaccharide (XOS) (46, 50). Further, the analysis of complete genomes from several commercial B. lactis strains, including B. lactis HN019™ supports this, as well as the identification of several putative carbohydrate-modifying enzymes in the genome of B. lactis HN019™ for a wide range of complex carbohydrates (97, 98). This is supported by the utilization of oligosaccharides by B. lactis HN019™ seems best for mono- and di-saccharides, such as stachyose, raffinose, but not able to utilize oligosaccharides with a degree of polymerization of more than 7 (99, 100). Such oligosaccharide utilization may contribute to a reduced fermentation by the endogenous microbiota and improve tolerance to such fibers. Bifidobacterium spp. are usually non-gas producers, since in general, they metabolize monosaccharides via the fructose-6-phosphate pathway eventually to SCFAs without gas as a by-product (98, 101). Therefore, endogenous and consumed bifidobacteria, including B. lactis HN019™, could divert the fermentation in the colon toward non-gaseous end-products. This property of B. lactis HN019™ may support tolerance for the fermentation of oligosaccharides in vivo, which is in line with clinical observations of B. lactis HN019™ on reduced flatulence (21, 32). In addition, lactate and acetate are produced during B. lactis HN019™ fermentation, indicating potential roles in digestion of dietary components without differentiation of the origin; carbohydrate or protein (89, 102).

Weak indications were observed for the involvement of B. lactis HN019™ in digestion of specific dietary component(s) in human (44). In this study, a combination of L. rhamnosus HN001 and B. lactis HN019™ was examined on established atopic dermatitis (AD) in children SCORAD (SCORing Atopic Dermatitis), a measure of the extent and severity of AD, was assessed at baseline, 2 and 12 weeks after starting treatment and 4 weeks after treatment was discontinued. The supplement alleviated AD symptoms, but only in a sub-group of food-sensitized children, whereas no effect on children sensitized to environmental allergens, suggesting the beneficial effect of the
probiotic may only relate to local effects on GIT, mainly toward food challenges (44). However, since the results came from sub-group analysis in children only tested for several common food allergens, the results should be interpreted with caution, and more confirmatory human studies should be carried out in larger population.

Gut microbial bile salt hydrolase (BSH) enzymes promote deconjugation, dehydrogenation, and dihydroxylation of primary bile acids, increasing the chemical diversity of bile acids, which can in turn have an impact on host lipid metabolism (93). Unconjugated bile acids are less efficient emulsifiers of dietary fats and may positively influence blood lipid profiles. Even though no data showed *B. lactis* HN019™ could deconjugate bile salts, as discussed earlier, *B. lactis* HN019™ may have a role in bile acid metabolism via affecting gut commensals, which in turn can change the amount of fat that the body is able to absorb. In addition, several studies have shown the potential of *B. lactis* HN019™ alone or in combination with other probiotics in improving blood lipid profiles (61, 63).

**DISCUSSION**

Different aspects of digestive health are the most common health benefits addressed by probiotics (103). The above review has shown that also *B. lactis* HN019™ has several health benefits in this area, in particular in the area of bowel function and intestinal motility. *Bifidobacterium animalis* subsp. *lactis* is one of the most common lactic acid producing probiotics in North-America and Europe (104). Its superiority in the dietary supplement and dairy industry has yielded several well-known commercial strains, such as *B. lactis* DN-173 010/ *B. lactis* CNCM I-2494 (Danone), BB-12 (Chr. Hansen), and the here discussed *B. lactis* HN019™ (International Flavors & Fragrances).

* B. lactis* DN-173010/ *B. lactis* CNCM I-2494 in fermented milk at a dosage of $1.25 \times 10^{10}$ CFU two to three times/day, has shown beneficial effects on acceleration of gastrointestinal transit in both a healthy and constipation dominant irritable bowel syndrome (IBS-C) population after 10 days (105–107). Moreover, this probiotic fermented milk (PFM) has been shown to improve general gastrointestinal well-being, reduce symptomatology including abdominal distention and discomfort in individuals from the general population with minor digestive symptoms but not functional gastrointestinal disorders (107–109), as well as in IBS-C population (106). These studies were all performed with fermented milk which also contained the classic yogurt cultures: *S. thermophilus* and *L. bulgaricus*. Noteworthy, both Guyonnet et al. (107) and Marteau et al. (109) recruited healthy women without any diagnosis of digestive disease, including FBD, such as IBS with normal BMF (3–21/week). This hypothesis was further confirmed, in rat model, where *B. lactis* CNCM I-2494 reduced stress-induced visceral hypersensitivity by restoring intestinal barrier function (110), and in a proof-of-concept study where healthy women consumed this PFM and modulation of brain activities related to mood was reported (111).

*B. lactis* BB-12 is another well-documented probiotic strain that has been investigated for its digestive health benefits (112). In several studies the strain has been evaluated for the effects it has on BMF. In a large study testing two doses; $10^9$ and $10^{10}$ CFU/day for four weeks, a beneficial effect was observed especially in the lower tested dose (113). Similarly, a fermented oat product with *B. lactis* BB-12 was observed to normalize bowel function in elderly. In combination with *Lactisaceibacillus paracasei* CRL-341 softer stools were observed (114). This could suggest a potential mechanism of action. A recent study was, however, not able to replicate the effect on intestinal transit time (115); most likely because of the small number of subjects and that subjects were not selected to have long transit times or be constipated. Consumption of yogurt or a capsule with the strain was not found to change the intestinal microbiota, this is not unusual; the resilience of a healthy colonic microbiota is likely to resist change from one (probiotic) strain (116). However, consumption of the probiotic yogurt did lead to fecal recovery of the strain (115).

In summary, all three *B. lactis* strains discussed above do seem to have quite similar effects on bowel movements. This is confirmed by a recent meta-analysis which concluded that *B. lactis* may be more effective in increasing stool frequency and in improving stool consistency (117). It is therefore tempting to speculate that this relates to the high genome similarity and almost complete synteny of the genomes between various strains within the subspecies *B. lactis* (97, 118). The small genetic difference between strains of *B. lactis* could be investigated further and correlated with phenotypic traits to help understand mechanisms of action.

As manifested by the current research, serotonin signaling pathway seems to be a major effector pathway underlining the efficacy of *B. lactis* HN019™ on gut motility, where SCFAs derived from gut microbial fermentation seem to be promising candidate effector molecules. The contribution from other bacterial derived molecules, such as formylated peptides acting on FPR1 cannot be ruled out with the current knowledge. Although probiotics in healthy subject generally cause no or minor changes in the gut microbiota (113); it nevertheless seems to be involved in the complex interactions of *B. lactis* HN019™ with host metabolisms and immune defenses, including endocrine cells, immune cytokines, and neurotransmitters, which are yet to be fully understood. Therefore, future investigations on the exact role of *B. lactis* HN019™ on gut motility should focus on identifying key molecules and signaling pathways in the gut–brain–microbiota interactions in humans, which could enhance our understanding. To this end, focus of microbiota analysis should shift or expand to the analysis of the colonic mucosal microbiota and metabolomics of the intestinal microbiota (119). Recent scientific advances suggest great potential for bacterial-derived microvesicles (MVs) on gut health. Microvesicles from *L. reuteri* DSM 17938 were shown in an *ex vivo* mouse colon to recapitulate the effects of the whole bacteria on increasing colonic propagating contraction frequency (120). Application of *L. rhamnosus* JB-1 and its MVs separately to the apical
side of the gut epithelium, could reduce the amplitude of propagating neural contractions in ex vivo mouse colon via interactions with ENS (121). These findings suggest a role for MVs from probiotics on signaling and their significance in the mechanisms of action within the gut-brain-microbiota axis, would therefore be potential mode of action to be investigated in the future for a better understanding of mechanisms of B. lactis HN019™.

In conclusion, B. lactis HN019™ has been observed to have benefits on different aspects of digestive health; not unlike some other commercial probiotic B. lactis strains. What is needed, however, is a better understanding of the mechanisms of action on how B. lactis HN019™ and probiotics in general function (122). Further, clinical trials should be better designed; taking into account the heterogeneity across different populations (123, 124) with sufficiently sized studies and clearly defined endpoints.

REFERENCES

1. Lei YM, Nair L, Alegre ML. The interplay between the intestinal microbiota and the immune system. Clin Res Hepatol Gastroenterol. (2015) 39:9–19. doi: 10.1016/j.clinre.2014.10.008
2. Jalanka J, Spiller R. Role of microbiota in the pathogenesis of functional disorders of the lower GI tract: work in progress. Neurogastroenterol Motil. (2017) 29:1–5. doi: 10.1111/nmm.13194
3. Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Mechanisms of action of probiotics. Adv Nutr. (2019) 10(Suppl 1):349–66. doi: 10.1093/advances/nmy063
4. Kechagia M, Basoulis D, Konstantopoulos D, Dimitriadis D, Gyftopoulou K, Skarmoutsou N, et al. Health benefits of probiotics: a review. ISRN Nutr. (2013) 2013:481651. doi: 10.5402/2013/481651
5. de Moreno de LeBlanc A, LeBlanc JG. Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications. World J Gastroenterol. (2014) 20:16518–28. doi: 10.3748/wjg.v20.i44.16518
6. Dimidi E, Christodoulides S, Scott SM, Whelan K. Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation. Adv Nutr. (2017) 8:484–94. doi: 10.3945/an.116.014407
7. Vighi G, Marucci F, Sensi L, Di Cara G, Frati F. Allergy and the gastrointestinal system. Clin Exp Immunol. (2008) 153(Suppl 1):3–6. doi: 10.1111/j.1365-2249.2008.03713.x
8. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. (2016) 14:e1002533. doi: 10.1371/journal.pbio.1002533
9. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. (2018) 57:1–24. doi: 10.1007/s00394-017-1445-8
10. Hill C, Guarner F, Reid G, Gibson GR, Merensten DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. (2014) 11:506–14. doi: 10.1038/nrgastro.2014.66
11. Sanders ME. Summary of probiotic activities of Bifidobacterium lactis HN019. J Clin Gastroenterol. (2006) 40:776–83. doi: 10.1097/01.mcg.0000225576.73385.f0
12. Morovic W, Roos P, Zabel B, Hidalgo-Canabarra C, Kiefer A, Arrangou R. Transcriptional and functional analysis of Bifidobacterium animalis subsp. lactis exposure to tetracycline. Appl Environ Microbiol. (2018) 84:e01999–18. doi: 10.1128/AEM.01999-18
13. Miller LE, Lehortanta L, Lehtinen MJ. Short-term probiotic supplementation enhances cellular immune function in healthy elderly: systematic review and meta-analysis of controlled studies. Nutr Res. (2019) 64:1–8. doi: 10.1016/j.nutres.2018.12.011
14. Boudichon F, Alper I, Bibiloni R, Dubois A, Laulund S, Miks M, et al. Inventory of microbial food cultures with safety demonstration in fermented food products. Bull Int Dairy Federat. (2018) 495:5–71.
15. Ricci A, Allende A, Bolton D, Chemaly M, Davies R, Girone R, et al. Scientific opinion on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA. EFSA J. (2017) 15:e04664. doi: 10.2903/j.efsa.2017.4664
16. National Health Commission of the People’s Republic of China. Food Safety Standards, Risk Surveillance and Assessment. (2011). Available online at: http://www.nhcf.gov.cn/sps/s7891/201111/a10fe4d8d1b57c98846492208486cc2.shtml (accessed November 12, 2021).
17. FDA. Generally Recognized as Safe (GRAS) Notice No. 445 (2012).
18. Valentini Neto J, Chella TP, Rudnik DP, Ribeiro SML. Effects of symbiotic supplementation on gut functioning and systemic inflammation of community-dwelling elders - secondary analyses from a randomized clinical trial. Arg Gastroenterol. (2020) 57:24–30. doi: 10.1590/0004-2803.20200000006
19. Botelho PB, Ferreira MVR, Araujo AM, Mendes MM, Nakano EY. Effect of multispecies probiotic on gut microbiota composition in individuals with intestinal constipation: a double-blind, placebo-controlled randomized trial. Nutrition. (2020) 78:110890. doi: 10.1016/j.nut.2020.1 0890
20. Maria Ferreira Pinheiro J, Nazaré Batista M, de Lima e Silva C, Nunes de Lima Barroso F, Torres de Paiva G, de Sousa Reboçaus A, et al. Efeito de um mix de probióticos na constipação funcional de mulheres adultas: um estudo randomizado duplo-cego. O Mun Saud. (2019) 43:622–39. doi: 10.15354/0143-7809.2019430622639
21. Airaksinen K, Yeung N, Lahtinen SJ, Huttunen T, Shanahan F, et al. The effect of a probiotic blend on gastrointestinal symptoms in constipated patients: a double blind, randomised, placebo controlled 2-week trial. Benef Microbes. (2019) 10:617–27. doi: 10.3920/BM2018.0163
22. Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC. Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in individuals with functional constipation: a double-blind, randomized, placebo-controlled, and dose-ranging trial. Gut Microbes. (2018) 9:236–51. doi: 10.1080/19490076.2017.1412908
23. Aoe S, Nakazawa Y, OHmIya S. Combined effect of a probiotic (Bifidobacterium) and a prebiotic (polydextrose) on the fecal microbiota and stool parameters of healthy young women. Integr Med Mol Med. (2017) 4:1. doi: 10.15761/immm.1000306
24. Hemalatha R, Ouwehand AC, Forsten SD, Geddan JB, Mamidi RS, Bhaskar V, et al. A community-based randomized double blind controlled trial of Lactobacillus paracasei and Bifidobacterium lactis on reducing risk for

AUTHOR CONTRIBUTIONS

JC, AL, and AO: conceptualization, review, and editing. JC and AO: original draft preparation. All authors have read and agreed to the published version of the manuscript.

ACKNOWLEDGMENTS

The authors would like to acknowledge Dr. Johanna Maukonen for constructive criticisms.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2021.790561/full#supplementary-material
diarrhea and fever in preschool children in an urban slum in India. *Eur J Food Res* (2014) 4:325–41. doi: 10.1007/s00226-014-12820

25. Hemalath R, Ouwehand AC, Saarinen MT, Prasad UV, Swetha K, Bhas kar. Effect of probiotic supplementation on total Lactobacill, bifidobacteria and short chain fatty acids in 2-3-year-old children. *Microb Ecol Health Dis.* (2017) 28:1298340. doi: 10.1080/16512235.2017.1298340

26. Magro DO, de Oliveira LM, Bernasconi I, Ruela Mde S, Credidio L, Barcelos IK, et al. Effect of yogurt containing polydextrose, Lactobacillus acidophilus NCFM and *Bifidobacterium lactis* HN019: a randomized, double-blind, controlled study in chronic constipation. *Nutr J.* (2014) 13:75. doi: 10.1186/1475-2891-13-75

27. Waitzberg DL, Logullo LC, Bittencourt AF, Torrinhas RS, Shiroma GM, Paulino NP, et al. Effect of synbiotic in constipated adult women - a randomized, double-blind, placebo-controlled study of clinical response. *Clin Nutr.* (2013) 32:27–33. doi: 10.1016/j.clnu.2012.08.010

28. Sazawal S, Dhingra U, Hiremath G, Sarkar A, Dhingra P, Dutta A, et al. Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial. *PLoS ONE.* (2010) 5:e12164. doi: 10.1371/journal.pone.0012164

29. Sazawal S, Dhingra U, Sarkar A, Dhingra P, Deb S, Marwah D, et al. Efficacy of milk fortified with a probiotic *Bifidobacterium lactis* (DR-10) and prebiotic galacto-oligosaccharides in prevention of morbidity and on nutritional status. *Asia Pac J Clin Nutr.* (2004) 13(Suppl):S28.

30. Prasad J, Sazawal S, Dhingra U, Gopal PK. Detection of viable *Bifidobacterium lactis* HN019 (DR10TM) in stools of children during a synbiotic dietary intervention trial. *Int Dairy J.* (2013) 30:64–7. doi: 10.1016/j.idairyj.2012.12.001

31. Oswari H, Prayitno L, Dwipoerwantoro PG, Firmansyah A, Makrides M, Lawley B, et al. Comparison of stool microbiota compositions, stool alpha1–foecal DR10TM, immune markers, and maternal micronutrients among *Bifidobacterium lactis* HN019 (DR10TM), inulin, and micronutrient fortified milk on nutritional status. *Nutrire.* (2019) 23:93–100. doi: 10.1080/1028415X.2018.1420300

32. Waller PA, Gopal PK, Leyer GJ, Ouwehand AC, Reifer C, Stewart M E, Murphy R, Morgan XC, Wang XY, Wickens K, Purdie G, Fitzharris P, et al. Eczema-protective probiotic alters infant gut microbiome functional capacity but not composition: sub-sample analysis from a RCT. *Clin Nutr.* (2013) 32:60–6. doi: 10.1016/j.clnu.2012.12.001

33. Sistek D, Kelly R, Wickens K, Stanley T, Fitzharris P, Crane J. Is the effect of probiotics on atopic dermatitis confined to food sensitized children? *Clin Exp Allergy.* (2006) 36:629–33. doi: 10.1111/j.1365-2222.2006.02485.x

34. Gill HS, Rutherford KJ, Cross ML. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. *J Clin Immunol.* (2001) 21:264–71. doi: 10.1023/a:1010797220804

35. Gopal PK, Sullivan PA, Smart JB. Utilisation of galacto-oligosaccharides as selective substrates for growth by lactic acid bacteria including *Bifidobacterium lactis* DR10 and *Lactobacillus rhamnosus* DR20. *Int Dairy J.* (2001) 11:19–25. doi: 10.1006/sj.160958-6946(01)00026-7

36. Gill HS, Rutherford KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic *Bifidobacterium lactis* HN019. *Am J Clin Nutr.* (2001) 74:833–9. doi: 10.1093/ajcn/74.6.833

37. Le Poul E, Loison C, Struyf S, Springael DJ, Lannoy V, Decobceq ME, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. *J Biol Chem.* (2003) 278:25481–9. doi: 10.1074/jbc.M304103200

38. Chiang BL, Sheih YH, Wang LH, Liao CK, Gill HS. Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (*Bifidobacterium lactis* HN019): optimization and definition of cellular immune responses. *Eur J Clin Nutr.* (2000) 54:849–55. doi: 10.1038/sj.ejcn.1601093

39. Mäkeläinen H, Saarinen M, Stowell J, Rautonen N, Ouwehand AC. Xylo-oligosaccharides and lactitol promote the growth of *Bifidobacterium lactis* and *Lactobacillus* species in pure cultures. *Benef Microbes.* (2010) 1:139–48. doi: 10.1039/BM0900029

40. Arunachalam K, Gill HS, Chandra RK. Enhancement of natural immune function by dietary consumption of *Bifidobacterium lactis* (HN019): a secondary study from a randomized clinical trial. *Nutr J.* (2000) 9:77349. doi: 10.1080/1028415X.2018.1420300

41. Yang W, Tian L, Luo J, Yu J. Ongoing supplementation of probiotics to cesarean-born neonates during the first month of life may impact the gut microbiota. *Am J Perinatol.* (2020) 38:1181–91. doi: 10.1055/s-0040-1710559

42. Louzada ER, Ribeiro SML. Symbiotic supplementation, systemic inflammation, and symptoms of brain disorders in elders: a secondary study from a randomized clinical trial. *Nutr Neurosci.* (2020) 23:93–100. doi: 10.1080/1028415X.2018.1477349

43. Slyker RM, Kang J, Van Zylo N, Barthow C, Wickens K, et al. Effect of early probiotic supplementation on childhood cognition, behaviour and mood: a randomised, placebo-controlled trial. *Acta Paediatr.* (2018) 107:2172–8. doi: 10.1111/apa.14590

44. Slyker RM, Coomarasamy C, Wickens K, Thompson JMD, Stanley T, Barthow C, et al. Exposure to antibiotics in the first 24 months of life and neurocognitive outcomes at 11 years of age. *Psychopharmacology (Berl).* (2019) 236:1573–82. doi: 10.1007/s00213-019-05216-0
66. Prasad J, Gill H, Smart J, Gopal PK. Selection and characterisation of Bifidobacterium lactis strains and impact on sensory acceptance of fermented milk. Int Food Res J. (2010) 17:25–31. doi: 10.1111/j.1745-4573.2009.00965.x

67. Hou H, Wang Y, Shi L, Zhu J, Zhang L, Guo Y, et al. Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli strain. Int Microbiol. (2017) 20(4):449–56. doi: 10.2478/im-2017-0040

68. Bifidobacterium lactis DR10 strains and their antagonistic activity against enteropathogenic Escherichia coli. Front Microbiol. (2016) 7:1233. doi: 10.3389/fmicb.2016.01233

69. Gopal PK, Prasad J, Smart J, Gill H. In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their potential use as probiotics. LWT - Food Sci Technol. (2013) 46(1):378–84. doi: 10.1016/j.lwt.2012.09.014

70. Prasad J, Gill H, Smart J, Gopal PK. Selection and characterisation of Lactobacillus and Bifidobacterium strains for use as probiotics. Dairy J. (1998) 8:99–100. doi: 10.1016/S0958-7494(98)00024-2

71. Harvath A, Leber B, Feldbacher N, Steinwendler M, Komarova I, Rainer F, et al. The effects of a multispecies probiotic on microbiome-related side effects of long-term proton pump inhibitor use: a pilot study. Sci Rep. (2020) 10:21732. doi: 10.1038/s41598-020-59550-x

72. Ayivi RD, Gawayali R, Krastanova A, Aljaloud SO, Worku M, Tahergorabi R, et al. Lactic acid bacteria: food safety and human health applications. Dairy (2020) 2:1002–32. doi: 10.3390/dairy100201002

73. Gerratzen T, Smidt H, Rijkers GT, de Vos WM. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr. (2011) 6:209–40. doi: 10.1007/s12263-011-0229-7

74. Rinninella E, Rauol P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. (2019). 7:141. doi: 10.3390/microorganisms7010014

75. Dinan TG, Cryan JF. Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration. J Physiol. (2017) 595:489–503. doi: 10.1113/JP273106

76. Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS ONE. (2010) 5:e10667. doi: 10.1371/journal.pone.0010667

77. Putaala H, Salusjarvi T, Nordstrom M, Sairinen M, Ouwehand AC, Bech Hansen E, et al. Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo-oxygenase expression. Res Microbiol. (2008) 159:692–8. doi: 10.1016/j.resmic.2008.08.002

78. Zhou JS, Gill HS. Immunostimulatory probiotic Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 do not induce pathological inflammation in mouse model of experimental autoimmune thyroiditis. Int J Food Microbiol. (2010) 103:97–104. doi: 10.1016/j.ifjfoodmicro.2010.01.031

79. Liu C, Zhang ZY, Dong K, Guo XK. Adhesion and immunomodulatory effects of Bifidobacterium lactis HN019 on intestinal epithelial cells INT-407. World J Gastroenterol. (2010) 16:2283–90. doi: 10.3748/wjg.v16.i18.2283

80. Shu Q, Qu F, Gill HS. Probiotic treatment using Bifidobacterium lactis HN019 reduces weaning diarrhea associated with rotavirus and Escherichia coli infection in a piglet model. J Pediatr Gastroenterol Nutr. (2001) 33:171–7. doi: 10.1097/00005176-200108000-00014

81. Shu Q, Lin H, Rutherford KF, Fenwick SG, Prasad J, Gopal PK, et al. Dietary Bifidobacterium lactis (HN019) enhances resistance to oral Salmonella enterica infection in mice. Microb Immunol. (2000) 44:213–22. doi: 10.1111/j.1348-4200.2000.tb02486.x

82. Shu Q, Gill HS. A dietary probiotic (Bifidobacterium lactis HN019) reduces the severity of Escherichia coli O157:H7 infection in mice. Med Microbiol Immunol. (2001) 189:147–52. doi: 10.1023/a:10044857.200418

83. Dalziel JE, Anderson RC, Peters JS, Lynch AT, Spencer NJ, Dekker J, et al. Promotility action of the probiotic Bifidobacterium lactis HN019 extract compared with prucalopride in isolated rat large intestine. Front Neurosci. (2017) 11:20. doi: 10.3389/fnins.2017.00020

84. Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil. (2007) 19(11):999–1007. doi: 10.1111/j.1365-3130.2007.00965.x

85. Chandrasekharan B, Saeedi BJ, Alam A, Houser M, Srinivasan S, Tansey M, et al. Interactions between commensal bacteria and enteric neurons, via FPR1 induction of ROS, increase gastrointestinal motility in mice. Gastroenterology. (2019) 157:179.e2–92.e2. doi: 10.1053/j.gastro.2019.03.045

86. Fukumoto S, Tatewaki M, Yamada T, Fuijmiya M, Mantych C, Voss M, et al. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol. (2003) 284:R1269–76. doi: 10.1152/jappl.00442.2002

87. Mitsui R, Ono S, Karaki S, Kuwahara A. Neural and non-neural mediation of propionate-induced contractile responses in the rat distal colon. Neurogastroenterol Motil. (2005) 17:585–94. doi: 10.1111/j.1365-3130.2005.00669.x

88. Tazoe H, Otomo Y, Kaji I, Tanaka R, Karaki S, Kuwahara A. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J Physiol Pharmacol. (2008) 59:251–62.

89. Henrique-Bana F, Macedo F Jr, Oliveira L, Takihara A, Miglioranza L, Spinosa W, et al. Bifidobacterium lactis HN019: survival, acid production and impact on sensory acceptance of fermented milk. Int Food Res J. (2019) 26:695–703.

90. Kamath PS, Phillips SF, Zinsmeister AR. Short-chain fatty acids stimulate ileal motility in humans. Gastroenterology. (1988) 95:1949–52. doi: 10.1016/s0016-5085(88)80068-4
91. Coremans G, Tack J, Vantrappen G, Janssens J, Annese V. Is the irritable bowel really irritable? Ital J Gastroenterol. (1991) 23(8 Suppl 1):39–40.
92. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. (2015) 161:264–76. doi: 10.1016/j.cell.2015.02.047
93. Enright EE, Griffin PT, Gahan CGM, Joyce SA. Microbiome-mediated bile acid modification: role in intestinal drug absorption and metabolism. Pharmaco Res. (2018) 133:170–86. doi: 10.1016/j.prrx.2018.04.009
94. Rao AS, Wong BS, Camilleri M, Carlson P, McKinzie S, Busciglio I, Bondar O, et al. Dose-response study of probiotic bacteria Bifidobacterium animalis subsp. lactis BB-12 and Lactobacillus paracasei subsp. paracasei CRL-3141 in healthy young adults. Eur J Clin Nutr. (2006) 60:1284–93. doi: 10.1038/sj.ejcn.1602450
95. Mayer TE, Guyonnet D, Lafaye de Micheaux P, Gelu S. A randomized, double-blind, controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifidobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms. Neur gastroenterol Motil. (2013) 25:331–c252. doi: 10.1111/nmo.12078
96. Wong BS, Camilleri M, Carlson P, McKinzie S, Busciglio I, Bondar O, et al. Consumption of fermented milk product containing probiotic Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats. Neur gastroenterol Motil. (2012) 24:376–e172. doi: 10.1111/j.1365-2982.2011.01865.x
97. Barrangou R, Briczinski EP, Traeger LL, Loquasto JR, Richards M, Horvath P, et al. Comparison of the complete genome sequences of Bifidobacterium animalis subsp. lactis DSM 10140 and BI-04. J Bacteriol. (2009) 191:414–51. doi: 10.1128/JB.00155-09
98. Leveque M, et al. A marketed fermented dairy product containing Bifidobacterium lactis HN019 and Lactobacillus acidophilus NCDC 532 improves defecation frequency in healthy volunteers. Clin Gastroenterol Hepatol. (2012) 10:1009.e3–15.x. doi: 10.1016/j.cgh.2012.05.006
99. Sims IM, Ryan JF, Kim SH. Bifidobacterium lactis strains may alter the delivery efficacy of Bifidobacterium animalis subsp. lactis BB-12(R), on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. Br J Nutr. (2015) 114:1638–46. doi: 10.1017/S0007114515003347
100. Agostini S, Goubern M, Tondereau V, Salvador-Cartier C, Bezirard V, et al. Bifidobacterium lactis CNCM I-2494 and Lactobacillus paracasei subsp. paracasei CRL-3141 modulate gut microbiota in healthy women: a double-blind, randomized, controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifidobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms. Neur gastroenterol Motil. (2013) 25:331–c252. doi: 10.1111/nmo.12078
101. Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. (2013) 144:1394–401. doi: 10.1053/j.gastro.2013.02.043
102. Dronkers TMG, Ouwehand AC, Rijkers GT. Data on global...
constipation: systematic review with meta-analysis. *Clin Med Insights Gastroenterol.* (2017) 11:1179552217729343. doi: 10.1177/1179552217729343

124. Miller LE, Ibarra A, Ouwehand AC, Zimmermann AK. Normative values for stool frequency and form using Rome III diagnostic criteria for functional constipation in adults: systematic review with meta-analysis. *Ann Gastroenterol.* (2017) 30:161–7. doi: 10.20524/aog.2016.0108

**Conflict of Interest:** At the time of writing, the authors were employed by International Flavors & Fragrances Inc. (IFF). IFF manufactures and markets *Bifidobacterium animalis* subsp. *lactis* HN019.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Cheng, Laitila and Ouwehand. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.